Chemotherapy: Open Access
Open Access

Yan Li

Publications

• Brief Report
  A Study Design: Concurrent EGFR-TKI and Thoracic Radiotherapy as Firstline Treatment of Stage IV NSCLC Patients with EGFR Active Mutations (CERTAIN Study)
  Author(s): Yan-Mei Wang, Yu-Zhong Duan, Rong-Xia Liao, Yan Li, Xu Chen and Jian-Guo Sun Yan-Mei Wang, Yu-Zhong Duan, Rong-Xia Liao, Yan Li, Xu Chen and Jian-Guo Sun
  
  Lung cancer is a common malignant tumor with high morbidity and mortality worldwide; more than 70 percent of patients are diagnosed with advanced disease. Nowadays, chemotherapy with concurrent thoracic radiotherapy (TRT) has been proven effective in stage IV NSCLC. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib and erlotinib, is the standard first-line treatment for stage IV non-small cell lung cancer (NSCLC) patients harboring EGFR active mutations. Previous in vitro studies showed that EGFR-TKI could sensitize tumor cells to radiation, and some researches indicated that EGFR mutations appear to be favorable predictive and prognostic factors in NSCLC patients treated with radiotherapy. A retrospective study has indicated that the combination of EGFR-TKI with TRT as the first-line treatment for advanced NSCLC was effective. However, the efficacy.. View More»
  DOI: 10.4172/2167-7700.1000186

  Abstract PDF

Relevant Topics